- Home
- FLC vs PLX Comparison
FLC vs PLX Comparison
Compare FLC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | PLX |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.4M | 182.9M |
| IPO Year | 2003 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FLC | PLX |
|---|---|---|
| Price | $15.63 | $2.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.4K | ★ 801.0K |
| Earning Date | 01-01-0001 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.33 | $1.65 |
| 52 Week High | $18.09 | $3.19 |
Technical Indicators
Market Signals| Indicator | FLC | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 46.73 |
| Support Level | $15.33 | $2.59 |
| Resistance Level | $15.85 | $2.75 |
| Average True Range (ATR) | 0.21 | 0.10 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 61.54 | 20.00 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.